嗜酸性粒细胞及其相关细胞因子在支气管哮喘中的研究进展
Research Advances in Eosinophils and Associated Cytokines in Bronchial Asthma
DOI: 10.12677/acm.2025.1551509, PDF,   
作者: 李 娅, 谭尧轩, 杨 艺：成都中医药大学临床医学院，四川 成都；王 慧*：成都市第一人民医院呼吸科，四川 成都
关键词: 支气管哮喘；嗜酸性粒细胞；细胞因子；气道炎症；靶向治疗；Bronchial Asthma； Eosinophils； Cytokines； Airway Inflammation； Targeted Therapy
摘要: 哮喘是一种以慢性气道炎症为特征的异质性疾病。临床表现为喘息、气促、胸闷和咳嗽等症状，这些症状随时间和强度而变化，且哮喘的气流受限是可逆的。哮喘的发病率呈逐年上升趋势，因此如何精准有效地控制及治疗是我们应该关注的重点。嗜酸性粒细胞作为核心成分参与了多种类型哮喘发病全过程，对其水平的监测能够充分反映患者气道炎症变化情况，对于患者病情评估具有重要的临床价值。现对嗜酸性粒细胞及其相关因子在支气管哮喘的国内外研究进展作一概述，为支气管哮喘的治疗提供理论依据。
Abstract: Asthma is a heterogeneous disease characterized by chronic airway inflammation. Its clinical manifestations include wheezing, shortness of breath, chest tightness, and cough, with symptoms varying in intensity and duration over time. Notably, asthma-associated airflow limitation is reversible. The escalating global prevalence of asthma underscores the urgency to prioritize precise and effective disease management and treatment strategies. Eosinophils, as a central component, are involved throughout the pathogenesis of various asthma subtypes. Monitoring eosinophil levels provides critical insights into dynamic changes in airway inflammation, offering substantial clinical value for disease assessment and therapeutic decision-making. This article synthesizes current domestic and international research advancements on eosinophils and their related factors in bronchial asthma, aiming to establish a theoretical foundation for optimizing asthma treatment protocols.
文章引用：李娅, 王慧, 谭尧轩, 杨艺. 嗜酸性粒细胞及其相关细胞因子在支气管哮喘中的研究进展[J]. 临床医学进展, 2025, 15(5): 1415-1422. https://doi.org/10.12677/acm.2025.1551509

参考文献

[1] Aoki, A., Hirahara, K., Kiuchi, M. and Nakayama, T. (2021) Eosinophils: Cells Known for over 140 Years with Broad and New Functions. Allergology International, 70, 3-8. [Google Scholar] [CrossRef] [PubMed]
[2] Muniz, V.S., Weller, P.F. and Neves, J.S. (2012) Eosinophil Crystalloid Granules: Structure, Function, and Beyond. Journal of Leukocyte Biology, 92, 281-288. [Google Scholar] [CrossRef] [PubMed]
[3] Matucci, A., Maggi, E. and Vultaggio, A. (2019) Eosinophils, the IL-5/IL-5Rα Axis, and the Biologic Effects of Benralizumab in Severe Asthma. Respiratory Medicine, 160, Article ID: 105819. [Google Scholar] [CrossRef] [PubMed]
[4] Farahi, N., Loutsios, C., Simmonds, R.P., Porter, L., Gillett, D., Heard, S., et al. (2014) Measurement of Eosinophil Kinetics in Healthy Volunteers. In: Walsh, G., Ed., Eosinophils, Springer, 165-176. [Google Scholar] [CrossRef] [PubMed]
[5] Wechsler, M.E., Munitz, A., Ackerman, S.J., Drake, M.G., Jackson, D.J., Wardlaw, A.J., et al. (2021) Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 96, 2694-2707. [Google Scholar] [CrossRef] [PubMed]
[6] Choi, Y., Luu, Q.Q. and Park, H. (2022) Extracellular Traps: A Novel Therapeutic Target for Severe Asthma. Journal of Asthma and Allergy, 15, 803-810. [Google Scholar] [CrossRef] [PubMed]
[7] Al Duhailib, Z., Farooqi, M., Piticaru, J., Alhazzani, W. and Nair, P. (2021) The Role of Eosinophils in Sepsis and Acute Respiratory Distress Syndrome: A Scoping Review. Canadian Journal of Anesthesia/Journal Canadien d’Anesthésie, 68, 715-726. [Google Scholar] [CrossRef] [PubMed]
[8] Pant, H., Hercus, T.R., Tumes, D.J., Yip, K.H., Parker, M.W., Owczarek, C.M., et al. (2023) Translating the Biology of Β Common Receptor-Engaging Cytokines into Clinical Medicine. Journal of Allergy and Clinical Immunology, 151, 324-344. [Google Scholar] [CrossRef] [PubMed]
[9] Morjaria, J.B., Emma, R., Fuochi, V., Polosa, R. and Caruso, M. (2019) An Evaluation of Mepolizumab for the Treatment of Severe Asthma. Expert Opinion on Biological Therapy, 19, 491-500. [Google Scholar] [CrossRef] [PubMed]
[10] Johnston, L.K., Hsu, C., Krier-Burris, R.A., Chhiba, K.D., Chien, K.B., McKenzie, A., et al. (2016) IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis. The Journal of Immunology, 197, 3445-3453. [Google Scholar] [CrossRef] [PubMed]
[11] Dolitzky, A., Grisaru‐Tal, S., Avlas, S., Hazut, I., Gordon, Y., Itan, M., et al. (2022) Mouse Resident Lung Eosinophils Are Dependent on IL‐5. Allergy, 77, 2822-2825. [Google Scholar] [CrossRef] [PubMed]
[12] Mümmler, C., Suhling, H., Walter, J., Kneidinger, N., Buhl, R., Kayser, M.Z., et al. (2022) Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice, 10, 3174-3183. [Google Scholar] [CrossRef] [PubMed]
[13] Komlósi, Z.I., van de Veen, W., Kovács, N., Szűcs, G., Sokolowska, M., O’Mahony, L., et al. (2022) Cellular and Molecular Mechanisms of Allergic Asthma. Molecular Aspects of Medicine, 85, Article ID: 100995. [Google Scholar] [CrossRef] [PubMed]
[14] Ferrante, G., Tenero, L., Piazza, M. and Piacentini, G. (2022) Severe Pediatric Asthma Therapy: Dupilumab. Frontiers in Pediatrics, 10, Article 963610. [Google Scholar] [CrossRef] [PubMed]
[15] Matucci, A., Bormioli, S., Nencini, F., Maggi, E. and Vultaggio, A. (2020) The Emerging Role of Type 2 Inflammation in Asthma. Expert Review of Clinical Immunology, 17, 63-71. [Google Scholar] [CrossRef] [PubMed]
[16] Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Armentaro, G., Calabrese, C., et al. (2022) Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 10, Article 974. [Google Scholar] [CrossRef] [PubMed]
[17] Tu, L., Chen, J., Zhang, H. and Duan, L. (2017) Interleukin-4 Inhibits Regulatory T Cell Differentiation through Regulating CD103+ Dendritic Cells. Frontiers in Immunology, 8, Article 214. [Google Scholar] [CrossRef] [PubMed]
[18] Rosenberg, H.F., Phipps, S. and Foster, P.S. (2007) Eosinophil Trafficking in Allergy and Asthma. Journal of Allergy and Clinical Immunology, 119, 1303-1310. [Google Scholar] [CrossRef] [PubMed]
[19] Komiya, A., Nagase, H., Yamada, H., Sekiya, T., Yamaguchi, M., Sano, Y., et al. (2003) Concerted Expression of Eotaxin-1, Eotaxin-2, and Eotaxin-3 in Human Bronchial Epithelial Cells. Cellular Immunology, 225, 91-100. [Google Scholar] [CrossRef] [PubMed]
[20] Busse, W.W., Kraft, M., Rabe, K.F., Deniz, Y., Rowe, P.J., Ruddy, M., et al. (2021) Understanding the Key Issues in the Treatment of Uncontrolled Persistent Asthma with Type 2 Inflammation. European Respiratory Journal, 58, Article ID: 2003393. [Google Scholar] [CrossRef] [PubMed]
[21] Steelant, B., Wawrzyniak, P., Martens, K., Jonckheere, A., Pugin, B., Schrijvers, R., et al. (2019) Blocking Histone Deacetylase Activity as a Novel Target for Epithelial Barrier Defects in Patients with Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 144, 1242-1253.e7. [Google Scholar] [CrossRef] [PubMed]
[22] Corren, J. (2013) Role of Interleukin-13 in Asthma. Current Allergy and Asthma Reports, 13, 415-420. [Google Scholar] [CrossRef] [PubMed]
[23] 徐庆雷, 周红, 马小波, 等. 哮喘患儿支气管肺泡灌洗液GM-CSF和MPO水平的变化及意义[J]. 检验医学, 2017, 32(7): 603-606.
[24] Wicks, I.P. and Roberts, A.W. (2015) Targeting GM-CSF in Inflammatory Diseases. Nature Reviews Rheumatology, 12, 37-48. [Google Scholar] [CrossRef] [PubMed]
[25] Acciani, T.H., Suzuki, T., Trapnell, B.C. and Le Cras, T.D. (2016) Epidermal Growth Factor Receptor Signalling Regulates Granulocyte-Macrophage Colony‐Stimulating Factor Production by Airway Epithelial Cells and Established Allergic Airway Disease. Clinical & Experimental Allergy, 46, 317-328. [Google Scholar] [CrossRef] [PubMed]
[26] Esnault, S., Kelly, E.A.B., Shen, Z., Johansson, M.W., Malter, J.S. and Jarjour, N.N. (2015) IL-3 Maintains Activation of the P90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils. The Journal of Immunology, 195, 2529-2539. [Google Scholar] [CrossRef] [PubMed]
[27] Willebrand, R. and Voehringer, D. (2016) IL-33-Induced Cytokine Secretion and Survival of Mouse Eosinophils Is Promoted by Autocrine GM-CSF. PLOS ONE, 11, e0163751. [Google Scholar] [CrossRef] [PubMed]
[28] Nobs, S.P., Kayhan, M. and Kopf, M. (2019) GM-CSF Intrinsically Controls Eosinophil Accumulation in the Setting of Allergic Airway Inflammation. Journal of Allergy and Clinical Immunology, 143, 1513-1524.e2. [Google Scholar] [CrossRef] [PubMed]
[29] Smith, R.J., et al. (2023) TNF-α-TNFR2 Axis Reprograms Mitochondrial Metabolism via mTORC1 in Eosinophils. Nature Immunology, 24, 234-245.
[30] 陈青云. MicroRNA223通过靶向STAT3调控Toll样受体触发的巨噬细胞IL-6和IL-1β的分泌[D]: [硕士学位论文]. 杭州: 浙江大学, 2012.
[31] Huang, Q., et al. (2023) IL-6/JAK1/STAT3/miR-155 Axis Suppresses Eosinophil Apoptosis via Bim Downregulation. Journal of Allergy and Clinical Immunology, 151, 225-238.
[32] Chen, S., Chen, Z., Deng, Y., Zha, S., Yu, L., Li, D., et al. (2022) Prevention of IL-6 Signaling Ameliorates Toluene Diisocyanate-Induced Steroid-Resistant Asthma. Allergology International, 71, 73-82. [Google Scholar] [CrossRef] [PubMed]
[33] Pilette, C., Canonica, G.W., Chaudhuri, R., Chupp, G., Lee, F.E., Lee, J.K., et al. (2022) REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 10, 2646-2656. [Google Scholar] [CrossRef] [PubMed]
[34] Kelly, E.A., Esnault, S., Liu, L.Y., Evans, M.D., Johansson, M.W., Mathur, S., et al. (2017) Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. American Journal of Respiratory and Critical Care Medicine, 196, 1385-1395. [Google Scholar] [CrossRef] [PubMed]
[35] Korn, S., Cook, B., Simpson, L.J., Llanos, J. and Ambrose, C.S. (2023) Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review. Advances in Therapy, 40, 2944-2964. [Google Scholar] [CrossRef] [PubMed]
[36] Nair, P., Bardin, P., Humbert, M., Murphy, K.R., Hickey, L., Garin, M., et al. (2020) Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 8, 555-564. [Google Scholar] [CrossRef] [PubMed]
[37] Pérez de Llano, L., Cosío, B., Lobato Astiárraga, I., Soto Campos, G., Tejedor Alonso, M., Marina Malanda, N., et al. (2023) First-Line versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma. Journal of Investigational Allergy and Clinical Immunology, 33, 220-222. [Google Scholar] [CrossRef] [PubMed]
[38] Dagher, R., Kumar, V., Copenhaver, A.M., Gallagher, S., Ghaedi, M., Boyd, J., et al. (2021) Novel Mechanisms of Action Contributing to Benralizumab’s Potent Anti-Eosinophilic Activity. European Respiratory Journal, 59, Article ID: 2004306. [Google Scholar] [CrossRef] [PubMed]
[39] Menzella, F., Biava, M., Bagnasco, D., Galeone, C., Simonazzi, A., Ruggiero, P., et al. (2019) Efficacy and Steroid-Sparing Effect of Benralizumab: Has It an Advantage over Its Competitors? Drugs in Context, 8, 1-11. [Google Scholar] [CrossRef] [PubMed]
[40] Vultaggio, A., Aliani, M., Altieri, E., Bracciale, P., Brussino, L., Caiaffa, M.F., et al. (2023) Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma Patients Treated for 96-Weeks: Data from the ANANKE Study. Respiratory Research, 24, Article No. 135. [Google Scholar] [CrossRef] [PubMed]
[41] Bergantini, L., d’Alessandro, M., Pianigiani, T., Cekorja, B., Bargagli, E. and Cameli, P. (2023) Benralizumab Affects NK Cell Maturation and Proliferation in Severe Asthmatic Patients. Clinical Immunology, 253, Article ID: 109680. [Google Scholar] [CrossRef] [PubMed]
[42] Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., et al. (2020) Dual Blockade of IL‐4 and IL‐13 with Dupilumab, an IL‐4Rα Antibody, Is Required to Broadly Inhibit Type 2 Inflammation. Allergy, 75, 1188-1204. [Google Scholar] [CrossRef] [PubMed]
[43] Freeman, C.M., Curtis, J.L. and Hastie, A.T. (2023) Finding the Right Biological: Eosinophil Subset Differences in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 208, 121-123. [Google Scholar] [CrossRef] [PubMed]
[44] 褚小娟, 杨文婷, 唐连涛, 等. 新型抗嗜酸性粒细胞药物在哮喘中应用的研究进展[J]. 中国医药, 2024, 19(6): 924-927.
[45] Szefler, S.J., Roberts, G., Rubin, A.S., Zielen, S., Kuna, P., Alpan, O., et al. (2022) Efficacy, Safety, and Tolerability of Lebrikizumab in Adolescent Patients with Uncontrolled Asthma (Acoustics). Clinical and Translational Allergy, 12, e12176. [Google Scholar] [CrossRef] [PubMed]
[46] Corren, J., Szefler, S.J., Sher, E., Korenblat, P., Soong, W., Hanania, N.A., et al. (2024) Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology: In Practice, 12, 1215-1224.e3. [Google Scholar] [CrossRef] [PubMed]
[47] Tollenaere, M., Litman, T., Moebus, L., Rodriguez, E., Stölzl, D., Drerup, K., et al. (2021) Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis Are Regulated by Interleukin-13 and Modulated by Tralokinumab in Vitro. Acta Dermato Venereologica, 101, adv00447. [Google Scholar] [CrossRef] [PubMed]
[48] Russell, R.J., Chachi, L., FitzGerald, J.M., Backer, V., Olivenstein, R., Titlestad, I.L., et al. (2018) Effect of Tralokinumab, an Interleukin-13 Neutralising Monoclonal Antibody, on Eosinophilic Airway Inflammation in Uncontrolled Moderate-to-Severe Asthma (MESOS): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial. The Lancet Respiratory Medicine, 6, 499-510. [Google Scholar] [CrossRef] [PubMed]
[49] 黄宝萱, 林晓彤, 张颖琳, 等. 基于ERK1/2信号通路的加味过敏煎对过敏性哮喘小鼠影响的机制研究[J]. 时珍国医国药, 2025, 36(2): 246-252.
[50] Cremer, P.C., Abbate, A., Hudock, K., McWilliams, C., Mehta, J., Chang, S.Y., et al. (2021) Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet Rheumatology, 3, e410-e418. [Google Scholar] [CrossRef] [PubMed]

为你推荐